Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription

Posted October 31, 2007

Phase 2 Prasugrel Studies Suspended Prior to Release of Major Phase 3 Trial
Analysis of: Phase 2 Prasugrel Studies Suspended Prior to Release of Major Phase 3 Trial | www.medscape.com
Author: GLG Member Program Contributor

The devil is in the details! Far from disappointing, the protocol ammendments (dosing) based on pharmacokinetic analysis that have been effected are both prudent and reassuring. Prasugrel dosing is likely being adjusted to reflect its metabolism in various patient populations including the elderly and...

Posted October 31, 2007

There is no reason to believe that prasugrel will be coming any time soon. While Dr. Ware may not have given the reasons for the suspension of the trials, the only reason to stop enrollment in a study of healthy volunteers is safety, as there is no efficacy end point. The only safety endpoint...

Posted October 31, 2007

New Allergic Rhinitis Treatment Avamys™ Receives Positive Opinion In Europe
Analysis of: New Allergic Rhinitis Treatment Avamys™ Receives Positive Opinion In Europe | www.medicalnewstoday.com
Author: GLG Member Program Contributor

The news has drawn attention to the effectiveness of Avamys, the only prescription nasal steroid spray to achieve consistent results in all clinical trials. The report published in the Medical News Today (www.medicalnewstoday.com) is a confirmation from the GlaxoSmithKline plc about getting...

Posted October 29, 2007

In terms of specific drugs, this is not a major change in the armamentarium available for treatment of allergic rhinitis/conjunctivitis.

Posted October 29, 2007

This is the European equivalent of Veramyst. The control of ocular symptoms is a major marketing push but raises a few questions. There are concerns regarding cataract formation with the higher potency steroid molecules. Although low bioavailability is shown, there must be some direct...

Posted October 24, 2007

The relieve of eye symptoms is an advantage, but a lot of doctors who treat patients suffering from allergic rhinoconjunctivitis choose antihistamines for them. If it´is really easier to use, it will meet the patients needs, a very important item for compliance with long-term treatments

Posted October 23, 2007

From the standpoint of what is clinically practical, Avamys is not a new drug: it is fluticasone in a nasal spray, available for years as Flonase, now off patent and available in the U.S. generically and as Veramyst (the same product as Avamys). Despite claims that Avamys/Veramyst is the first drug...

Posted October 22, 2007

Novel agent for treatment of cerebral stroke and other diseases with neuronal damage in clinical phase I
Analysis of: Novel agent for treatment of cerebral stroke and other diseases with neuronal damage in clinical phase I | www.pipelinereview.com
Author: GLG Member Program Contributor

Separation of brain effects from stem cell proliferative effect is plausible. However, the establishment of efficacy in stroke models has not been very predictive in the past.

Posted October 22, 2007

Micro-bubble Contrast Agents (marketed as Definity (Perflutren Lipid Microsphere) Injectable Suspension and Optison (Perflutren Protein-Type A Microspheres for Injection)
Analysis of: Micro-bubble Contrast Agents (marketed as Definity (Perflutren Lipid Microsphere) Injectable Suspension and Optison (Perflutren Protein-Type A Microspheres for Injection) | www.fda.gov
Author: GLG Member Program Contributor

This recent notice from the FDA is significant in that it identfies specfic serious concerns regarding the safe use of micro-bubble type contrast agents in certain clinical setting where echocardiography is commonly used to assess heart disease. Physicians using these contrast agents...

Posted October 19, 2007

Enrollment Reaches 110 Patients In Investigator Initiated, Randomized Trial Of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM)
Analysis of: Enrollment Reaches 110 Patients In Investigator Initiated, Randomized Trial Of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) | www.medicalnewstoday.com
Author: GLG Member Program Contributor

The failure of drug eluting stents in the eyes of the public and in the medical community is probably not a failure of the device as much as a failure of patient managment. It is clear that atherothrombotic vascular disease requires a life-long commitment to blood pressure, cholesterol, and blood...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next101 to 110 of 395

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-08-29T21:45:17.707

All GLG News Analyses Filed Under: Cardiology

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare